Home › Carcinoma uroteliale (a cellule transizionali) › Tennessee › Nashville
Studi clinici su Carcinoma uroteliale (a cellule transizionali) a Nashville, TN
23 studi su Carcinoma uroteliale (a cellule transizionali) cercano partecipanti presso sedi a Nashville e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- Tennessee Oncology, Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #3, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
In reclutamentoFase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
In reclutamentoFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
In reclutamentoFase 3
- SCRI Oncology Partners, Nashville
DBC-664 in Adult Patients With Solid Tumors
In reclutamentoFase 1
- SCRI Oncology Partners, Nashville
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
In reclutamentoStudio osservazionale
- Vanderbilt University Medical Center, Nashville
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
In reclutamentoFase 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology, Nashville
- e altri 9
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
In reclutamentoFase 1
- Sarah Cannon Research Institute, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
In reclutamentoFase 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
In reclutamentoFase 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
In reclutamentoFase 2/3
- Research Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
In reclutamentoFase 1
- Sarah Cannon Research Institute, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
In reclutamentoFase 1/2
- Tennessee Oncology, Nashville
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
In reclutamentoFase 2/3
- Research Site, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
In reclutamentoFase 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
In reclutamentoFase 1/2
- SCRI Oncology Partners, Nashville
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
In reclutamentoFase 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
In reclutamentoFase 2
- SCRI Oncology Partners, Nashville
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
In reclutamento
- Vanderbilt University Medical Center, Nashville
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
In reclutamentoFase 2
- Site 02-007 - Urology Associates, P. C, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Nashville
Studi su Carcinoma uroteliale (a cellule transizionali) in altre città
- New York City, NY22 studi
- Houston, TX19 studi
- Dallas, TX18 studi
- Edison, NJ18 studi
- Los Angeles, CA17 studi
- Queens, NY15 studi
- Chicago, IL14 studi
- Arlington, VA12 studi
- Boston, MA11 studi
- San Antonio, TX11 studi
- Austin, TX10 studi
- Orange, CA10 studi
Altri studi a Nashville
- Cancro del polmone non a piccole cellule97 studi
- Cancro al seno81 studi
- Cancro metastatico70 studi
- Cancro colorettale69 studi
- Cancro (tutti i tipi)65 studi
- Cancro ovarico49 studi
- Cancro alla prostata43 studi
- Cancro ai polmoni40 studi
- Carcinoma a cellule squamose della testa e del collo39 studi
- Cancro pancreatico39 studi
- Cancro dell'endometrio38 studi
- Melanoma33 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.